Haemonetics wins patent infringement case against Fenwal

June 4, 2009 by MassDevice staff

Braintree blood management firm wins nearly $16 million in damages, 10 percent royalties and an injunction against further sales of the Illinois company's Alyx disposable blood collection kits; Fenwal to appeal.

Haemonetics Corp. won a patent infringement suit against Fenwal Inc., which said it plans to appeal the decision.

The ruling, issued in Boston Monday by Judge Nathaniel Gorton of the U.S. District Court, follows a jury's decision that a component of the Lake Zurich, Ill.-based blood management products maker's Alyx blood collection system infringes a patent held by Haemonetics. The jury awarded the Braintree firm $15.7 million in damages for the infringement.

Gorton further ruled that Fenwal must stop selling the consumable by Dec. 1, 2010, pay Haemonetics a 10 percent royalty on net sales of the kit from Jan. 30 until the injunction takes effect and pay 5 percent pre-judgment interest on the damages.

Fenwal said it planned to appeal the ruling and would, in the meantime, remove the infringing component from the kit before the end of the year.